Edition:
United States

Indivior PLC (INDV.L)

INDV.L on London Stock Exchange

362.31GBp
7:21am EDT
Change (% chg)

1.31 (+0.36%)
Prev Close
361.00
Open
360.70
Day's High
363.40
Day's Low
358.20
Volume
582,207
Avg. Vol
2,521,650
52-wk High
504.60
52-wk Low
246.50

Select another date:

Mon, Jun 18 2018

Indivior shares rise after U.S. court order blocks generic rival drug

June 18 Shares in British drugmaker Indivior rose on Monday after a U.S. Court granted a temporary restraining order blocking Dr. Reddy's Laboratories from launching a generic version of Indivior's best-selling opioid addiction treatment.

Indivior shares dive after Dr Reddy's gets FDA approval for generic

Britain's Indivior fell by more than 20 percent on Friday after the U.S Food and Drug Administration (FDA) approved the first generic versions of Suboxone Film, an opioid addiction treatment that generates 80 percent of its revenue.

UK's Indivior to seek injunction after rival gets FDA approval for generics

June 15 Britain's Indivior said on Friday it would pursue all legal remedies, including seeking an immediate injunction against the U.S Food and Drug Administration's (FDA) decision to approve the first generic versions of Suboxone Film, an opioid addiction treatment.

Indivior shares dive after Dr Reddy's gets FDA approval for generic

June 15 Britain's Indivior fell by more than 20 percent on Friday after the U.S Food and Drug Administration (FDA) approved the first generic versions of Suboxone Film, an opioid addiction treatment that generates 80 percent of its revenue.

Indivior subpoenaed by California on opioid addiction treatment

Britain's Indivior has been subpoenaed by the California Department of Insurance over its blockbuster opioid addiction treatment, Suboxone Film, which is rapidly losing market share due to stiff competition from generic versions.

UPDATE 1-Indivior subpoenaed by California on opioid addiction treatment

May 31 Britain's Indivior has been subpoenaed by the California Department of Insurance over its blockbuster opioid addiction treatment, Suboxone Film, which is rapidly losing market share due to stiff competition from generic versions.

UPDATE 2-Indivior's Q1 profit slips, shares fall on top drug let-down

* Company to share Sublocade sales of data in Q2 (Adds shares, analyst comment, details on Sublocade)

BRIEF-Indivior Posts Q1 profit down 5 pct

* Q1 NET REVENUE DECLINED 4 PCT (MINUS 6 PCT AT CONSTANT CURRENCY) TO $255M (Q1 2017: $265M)

Britain's Indivior Q1 profit down 5 pct

May 2 Britain's Indivior posted a 5 percent fall in quarterly profit, bogged down by a drop in U.S. market share for its best-selling treatment, Suboxone Film, due to competition from generic versions.

BRIEF-Indivior Says Filed NDS With Health Canada's For Sublocade Injection

* FILED A NEW DRUG SUBMISSION (NDS) WITH HEALTH CANADA'S THERAPEUTIC DRUGS DIRECTORATE FOR SUBLOCADE INJECTION Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Select another date: